Philip Huxley
Vorstandsvorsitzender bei Ducentis BioTherapeutics Ltd.
Aktive Positionen von Philip Huxley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Ducentis BioTherapeutics Ltd.
Ducentis BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Ducentis Biotherapeutics Ltd. develops novel therapies for inflammation and autoimmune disease. The company was founded by Rebecca Ashfield, David Blackbourn and Philip Huxley in March 2015 and is headquartered in Witney, the United Kingdom. | Vorstandsvorsitzender | 12.11.2014 | - |
Gründer | 12.11.2014 | - |
Karriereverlauf von Philip Huxley
Ehemalige bekannte Positionen von Philip Huxley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Corporate Officer/Principal | - | - |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | - | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Corporate Officer/Principal | - | - |
VERNALIS | Corporate Officer/Principal | - | - |
NOVARTIS AG | Corporate Officer/Principal | - | - |
Prexa Pharmaceuticals, Inc.
Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Philip Huxley
University of Aberdeen | Undergraduate Degree |
University of Sussex | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 7 |
Vereinigte Staaten | 2 |
Schweiz | 2 |
Operativ
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private Unternehmen | 6 |
---|---|
Prexa Pharmaceuticals, Inc.
Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Health Technology |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Health Technology |
Ducentis BioTherapeutics Ltd.
Ducentis BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Ducentis Biotherapeutics Ltd. develops novel therapies for inflammation and autoimmune disease. The company was founded by Rebecca Ashfield, David Blackbourn and Philip Huxley in March 2015 and is headquartered in Witney, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Philip Huxley
- Erfahrung